Preventing Infusion Reactions With CD20 Antibodies in CLL


For High-Definition, Click

Anti-CD20 antibodies, such as rituximab, obinutuzumab, and ofatumumab, have demonstrated good efficacy as treatments for patients with chronic lymphocytic leukemia (CLL), states Richard R Furman, MD. These antibodies have been studied in combination with chlorambucil in clinical studies, although Furman notes that it is unclear whether chlorambucil is necessary, particularly since it is an alkylating agent that may damage bone marrow.

Ofatumumab and obinutuzumab are generally well tolerated, but are associated with infusion reactions. It is important to choose patients wisely to identify individuals who are at high-risk for having an infusion reaction, notes Furman. Since patient selection is difficult, administration methods for lessening this adverse event should be utilized.

The original design of the obinutuzumab studies administered 1000 mg on day 1 but was altered to 100 mg on day 1 and 900 mg on day 2. Reducing the dose on the first day reduced lymphocytosis and dramatically improved tolerability, comments Furman. Also noteworthy is that the pivotal study involving idelalisib showed that administering idelalisib to patients as little as 2 hours before they were to receive their rituximab infusion reduced infusion reactions.

Related Videos
James K. McCloskey, MD, an expert on leukemia
James K. McCloskey, MD, an expert on leukemia
Amy DeZern, MD, MHS, an expert on MDS
Andrew Brunner, MD, an expert on MDS
Mitchell S. Cairo, MD, and Sergio Giralt, MD, experts on veno-occlusive disease
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital